| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2800265404012 | 26540401 | DOGMATYL CAPS 50MG/CAP BTx24(BLIST2x12) | 1.34 | 1.41 | 1.94 |
| 05/2018 | 2800265404043 | 26540404 | DOGMATYL CAPS 50MG/CAP BTx24(BLIST1x24) | 1.18 | 1.24 | 1.71 |
Sulpiride is indicated for the treatment of schizophrenia.
In contrast to most other neuroleptics which block both dopamine D1 and D2 receptors, Sulpiride is more selective and acts primarily as a dopamine D2 antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.
Sulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trism. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur.
Sulpiride is absorbed slowly from the gastrointestinal tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences.
6 to 8 hours